Ability of a new oral nicotine substitute to reduce smoking urge in moderate smokers.
The aim of this study was to assess the effectiveness of a new nicotine lozenge ( Nicopass 1.5 mg) in reducing smoking urge after an overnight abstinence. Twenty-four moderate smokers participated in a randomized, double-blind, placebo-controlled, 2-period crossover trial. The results showed that 1.5 mg-nicotine lozenge is superior to placebo in reducing smoking urge (p = 0.0001). In addition, nicotine lozenge, but not placebo, significantly improved vigilance and psychomotor performances (p < 0.05) and displayed a cardiac chronotropic effect. Thus, the 1.5-mg nicotine lozenge appears as an effective aid to alleviate acute tobacco withdrawal symptoms in moderate smokers.
Demazières
A
A
FORENAP Research Institute for Neuroscience, Pharmacology and Psychiatry, 27 rue du 4eme RSM, 68250 Rouffach, France. agnes.demazieres@forenap.asso.fr
Luthringer
R
R
Coppel
E
E
Gilles
C
C
Fleury
C
C
Roegel
J C
JC
Delarue
A
A
Laur
C
C
Lagrue
G
G
D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009538:Nicotine / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects; D012907:Smoking / Q000009:adverse effects / Q000188:drug therapy* / Q000523:psychology; D016540:Smoking Cessation / Q000379:methods*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000209:etiology
D018722:Nicotinic Agonists; D009538:Nicotine